A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

Also called NCT02512068

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 107 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02512068
  • WHO UTN U1111-1172-1511
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02512068. Randomized; quadruple masking; primary purpose treatment. Start 2015-08-07 (actual); primary completion 2018-04-24 (actual). Results posted on 2019-11-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Trelagliptin 25 mg
Intervention (Drug)
Placebo
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct02512068
Content hash
529123ec71716f995fd995ce7c128c95126d0e6a01a085f057d18dcd7b78f182